Dr. Caron A. Jacobson discusses the potential long-term impact of Yescarta for patients with relapsed or refractory indolent non-Hodgkin lymphoma and how it could turn an incurable disease into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results